FV-ARG-506-GLN-Mutation-associated resistance to activated protein C in ischemic stroke

T Tatlisumak; M Syrjälä; P Lindsberg; A Palotie; M Kaste

doi:10.1016/S1052-3057(10)80189-2

FV-ARG-506-GLN-Mutation-associated resistance to activated protein C in ischemic stroke

J Stroke Cerebrovasc Dis. 1995;5(4):192-6. doi: 10.1016/S1052-3057(10)80189-2. Epub 2010 Jun 10.

Authors

T Tatlisumak¹, M Syrjälä², P Lindsberg³, A Palotie⁴, M Kaste¹

Affiliations

¹ Department of Neurology, Helsinki University Central Hospital, Haart-maninkatu, Helsinki, Finland.
² Department of Neurology, Helsinki University Central Hospital, Haart-maninkatu, Helsinki, Finland; Department of Clinical Chemistry, Helsinki University, Haart-maninkatu, Helsinki, Finland.
³ Laboratory Department, Helsinki University Central Hospital, Haart-maninkatu, Helsinki, Finland.
⁴ Laboratory Department, Helsinki University Central Hospital, Haart-maninkatu, Helsinki, Finland; Department of Clinical Chemistry, Helsinki University, Haart-maninkatu, Helsinki, Finland.

PMID: 26486947
DOI: 10.1016/S1052-3057(10)80189-2

Abstract

A recently described coagulation disorder [FV-Arg-506-Gln-mutation-associated resistance to activated protein C (APC-resistance)] leads to a five- to tenfold increased risk for venous thromboembolism. The aim of the study was to determine if this disorder also predisposes to ischemic stroke. Ninety-nine consecutive patients with ischemic stroke of noncardiac origin were screened for APC-resistance and tested for the FV-Arg-506-Gln mutation. The FV-Arg-506-Gln mutation was found in 5 of the 99 stroke patients and in 6% of a pool of blood donors. FV-Arg-506-Gln mutation is not a major cause of ischemic stroke. However, a minor predisposing effect cannot be excluded. Further studies with larger stroke populations and subpopulations are indicated to determine the exact impact of this condition on ischemic stroke.